

Financial news for RIGL dated on 2020-06-08: Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.

Financial news for RIGL dated on 2020-05-27: JP Morgan Maintains Overweight on Rigel Pharmaceuticals, Lowers Price Target to \$6

Financial news for RIGL dated on 2020-05-05: Rigel Pharmaceuticals Q1 EPS \$0.130, Inline, Sales \$55.761M Miss \$56.710M Estimate

Financial news for RIGL dated on 2020-05-05: Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session.

Financial news for RIGL dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for RIGL dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for RIGL dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for RIGL dated on 2020-03-20: The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company

Financial news for RIGL dated on 2020-03-19: Stocks That Hit 52-Week Lows On Thursday

Financial news for RIGL dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for RIGL dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for RIGL dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for RIGL dated on 2020-02-27: Rigel Pharmaceuticals Q4 EPS \$(0.1) Misses \$(0.08) Estimate, Sales \$15.4M Miss \$15.62M Estimate

Financial news for RIGL dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for RIGL dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for RIGL dated on 2020-02-20: 22 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for RIGL dated on 2020-01-23: 15 Biotechnology Stocks Moving In Thursday's After-Market Session

Financial news for RIGL dated on 2020-01-23: 20 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for RIGL dated on 2020-01-23: 146 Biotechnology Stocks Moving In Thursday's Session

Financial news for RIGL dated on 2020-01-23: 70 Biggest Movers From Yesterday

Financial news for RIGL dated on 2020-01-22: 98 Biotechnology Stocks Moving In Wednesday's Session

Financial news for RIGL dated on 2020-01-22: 116 Healthcare Stocks Moving In Wednesday's Session

Financial news for RIGL dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for RIGL dated on 2020-01-17: 76 Biggest Movers From Yesterday

Financial news for RIGL dated on 2020-01-16: Rigel Pharmaceuticals shares are trading higher. Not seeing any company-specific news to justify the price action.

Financial news for RIGL dated on 2020-01-16: Stocks That Hit 52-Week Highs On Thursday

Financial news for RIGL dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for RIGL dated on 2020-01-15: Stocks That Hit 52-Week Highs On Wednesday

Financial news for RIGL dated on 2020-01-15: 80 Biggest Movers From Yesterday

Financial news for RIGL dated on 2020-01-14: 48 Stocks Moving In Tuesday's Mid-Day Session

Financial news for RIGL dated on 2020-01-14: Rigel Pharmaceuticals shares are trading higher on above-average volume. Not seeing any news to justify the price action.

Financial news for RIGL dated on 2020-01-13: Rigel Pharmaceuticals Sees Prelim. Q4 Net Product Sales \$13.8M, Total Revenues ~\$15.9M

Financial news for RIGL dated on 2019-12-18: The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data

Financial news for RIGL dated on 2019-12-09: BMO Capital Maintains Outperform on Rigel Pharmaceuticals, Lowers Price Target to \$8

Financial news for RIGL dated on 2019-11-15: 35 Stocks Moving in Friday's Pre-Market Session

Financial news for RIGL dated on 2019-11-15: Rigel Reports Positive CHMP Opinion For Fostamatinib Disodium Hexahydrate For Adult Patients With Chronic Immune Thrombocytopenia In Europe

Financial news for RIGL dated on 2019-11-15: Cantor Fitzgerald Maintains Overweight on Rigel Pharmaceuticals, Lowers Price Target to \$5

Financial news for RIGL dated on 2019-11-05: Rigel Pharmaceuticals Q3 EPS \$(0.07) Beats \$(0.13) Estimate, Sales \$11.716M Miss \$11.95M Estimate

Financial news for RIGL dated on 2019-11-01: Rigel Pharmaceuticals shares are trading higher despite no company-specific news. This could potentially be in sympathy with Immunogen after the company reported better-than-expected Q3 earnings results.

Financial news for RIGL dated on 2019-10-29: 46 Biggest Movers From Yesterday

Financial news for RIGL dated on 2019-10-28: Rigel Pharmaceuticals shares are trading higher. Not yet seeing any company-specific news.

Financial news for RIGL dated on 2019-10-24: Rigel Pharmaceuticals shares are trading higher on seemingly no company-specific news.

Financial news for RIGL dated on 2019-10-23: Rigel Pharmaceuticals Provides Business Update Prior To Investor & Analyst Call

Financial news for RIGL dated on 2019-10-18: Stocks That Hit 52-Week Lows On Friday

Financial news for RIGL dated on 2019-10-18: 32 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for RIGL dated on 2019-10-18: Rigel Pharma Reports Positive Trend Vote From CHMP For Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia In Europe

Financial news for RIGL dated on 2019-10-18: The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe

Financial news for RIGL dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for RIGL dated on 2019-09-26: 21 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for RIGL dated on 2019-09-24: Shares of many pharma/therapeutics

stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for RIGL dated on 2019-09-23: Rigel's fostamatinib Enters Phase 3 Clinical Trial In Japan With Kissei Pharmaceuticals For The Treatment Of Chronic Immune Thrombocytopenia

Financial news for RIGL dated on 2019-09-12: Rigel Pharmaceuticals shares are trading lower. The stock broke below the \$2 support level and continued to trade lower ever since.

Financial news for RIGL dated on 2019-09-04: Stocks That Hit 52-Week Lows On Wednesday

Financial news for RIGL dated on 2019-09-04: The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

Financial news for RIGL dated on 2019-08-28: The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved

Financial news for RIGL dated on 2019-08-16: The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission

Financial news for RIGL dated on 2019-08-06: Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for RIGL dated on 2019-08-06: Rigel Pharmaceuticals Q2 EPS \$(0.12) Beats \$(0.14) Estimate, Sales \$10.41M Beat \$9.28M Estimate

Financial news for RIGL dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for RIGL dated on 2019-05-16: Rigel Pharma Reports First Patient Enrolled In Phase 3 Trial Of Fostamatinib Disodium Hexahydrate In Warm Autoimmune Hemolytic Anemia

Financial news for RIGL dated on 2019-05-07: Rigel Pharmaceuticals Opened Clinical Trial Sites For Phase 3 Study Of Fostamatinib In Warm Autoimmune Hemolytic Anemia; Expects To Enroll First Patient This Month

Financial news for RIGL dated on 2019-05-07: Rigel Pharmaceuticals Q1 EPS \$(0.11) Beats \$(0.13) Estimate, Sales \$12.624M Beat \$11.37M Estimate

Financial news for RIGL dated on 2019-05-07: The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex

Financial news for RIGL dated on 2019-02-28: Rigel Pharmaceuticals Q4 EPS \$0.02 Misses \$0.03 Estimate, Sales \$37.86M Beat \$36.35M Estimate

Financial news for RIGL dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for RIGL dated on 2019-01-23: Rigel Rises On European Marketing Agreement For Autoimmune Drug

Financial news for RIGL dated on 2019-01-23: Rigel Pharmaceuticals Enters Collaboration And License Agreement With Grifols, S.A. To Commercialize Fostamatinib In Europe; Co. To Receive \$30M Upfront Cash Payment With \$297.5M In Potential Milestones

Financial news for RIGL dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for RIGL dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for RIGL dated on 2018-12-18: Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved

Financial news for RIGL dated on 2018-11-06: Rigel Pharmaceuticals, Inc. Q3 EPS \$(0.14) Beats \$(0.15) Estimate, Sales \$4.865M Beat \$3.93M Estimate

Financial news for RIGL dated on 2018-11-06: The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

Financial news for RIGL dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for RIGL dated on 2018-10-29: Rigel Pharma Enters Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize TAVALISSE in Japan and other Asian Countries

Financial news for RIGL dated on 2018-10-11: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for RIGL dated on 2018-10-11: Rigel Pharma Reports Received EMA Validation Of Marketing Authorization Application For Fostamatinib Disodium Hexahydrate In Chronic ITP In Adult Patients

Financial news for RIGL dated on 2018-09-21: 56 Biggest Movers From Yesterday

Financial news for RIGL dated on 2018-08-29: 40 Biggest Movers From Yesterday

Financial news for RIGL dated on 2018-08-28: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for RIGL dated on 2018-08-28: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for RIGL dated on 2018-08-27: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for RIGL dated on 2018-08-27: Benzinga's Top Upgrades, Downgrades For August 27, 2018

Financial news for RIGL dated on 2018-08-27: 24 Stocks Moving In Monday's Pre-Market Session

Financial news for RIGL dated on 2018-08-27: Citigroup Initiates Coverage On Rigel Pharmaceuticals with Buy Rating, Announces \$8.50 Price Target

Financial news for RIGL dated on 2018-08-10: 77 Biggest Movers From Yesterday

Financial news for RIGL dated on 2018-08-09: 68 Stocks Moving In Thursday's Mid-Day Session

Financial news for RIGL dated on 2018-08-09: Rigel Pharmaceuticals shares are trading 14.6% higher after announcing quarterly financial results anchored by strong sales figures.

Financial news for RIGL dated on 2018-08-09: The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Financial news for RIGL dated on 2018-08-09: 40 Stocks Moving In Thursday's Pre-Market Session

Financial news for RIGL dated on 2018-08-08: Rigel Pharma shares up 8.6% after hours following a Q2 loss which was inline with analysts' consensus estimate but very strong sales figures.

Financial news for RIGL dated on 2018-08-08: Rigel Pharmaceuticals Q2 EPS \$(0.16), Inline, Sales \$1.787M Beat \$180K Estimate

Financial news for RIGL dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for RIGL dated on 2018-06-26: Rigel Initiates Phase 1 Clinical Trial Of R835, An IRAK1/4 Inhibitor For Autoimmune And Inflammatory Diseases

Financial news for RIGL dated on 2018-06-21: Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street

Financial news for RIGL dated on 2018-06-12: Rigel To Present Phase 2 Results For Fostamatinib In Autoimmune Hemolytic Anemia At EHA

Financial news for RIGL dated on 2018-06-12: 44 Biggest Movers From Yesterday

Financial news for RIGL dated on 2018-06-11: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for RIGL dated on 2018-05-31: 41 Biggest Movers From Yesterday

Financial news for RIGL dated on 2018-05-30: Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immuteq Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

Financial news for RIGL dated on 2018-05-30: Rigel Names Dean Schorno CFO

Financial news for RIGL dated on 2018-05-29: Rigel Announces Availability of TAVALISSE

Financial news for RIGL dated on 2018-05-02: Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

Financial news for RIGL dated on 2018-05-01: Rigel Pharmaceuticals Q1 EPS \$(0.17) Inline

Financial news for RIGL dated on 2018-05-01: Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings

Financial news for RIGL dated on 2018-04-30: Rigel Pharmaceuticals Reports TAVALISSE Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo

Financial news for RIGL dated on 2018-04-29: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Financial news for RIGL dated on 2018-04-20: Rigel Prices 16M Share Public Offering Of Common Stock @\$3.90/Share

Financial news for RIGL dated on 2018-04-19: Benzinga Pro's Most-Searched Tickers For Morning Of Thurs., Apr. 19, 2018

Financial news for RIGL dated on 2018-04-18: Rigel Pharma Reports 15M Share Common Stock Offering

Financial news for RIGL dated on 2018-04-18: Analysts See 100% Upside To Rigel After Tavalisse Approval

Financial news for RIGL dated on 2018-04-18: Benzinga Pro's Most-Searched Tickers For Wed., Apr. 18, 2018

Financial news for RIGL dated on 2018-04-18: Benzinga Pro's 5 Stocks To Watch Today

Financial news for RIGL dated on 2018-04-18: 24 Stocks Moving In Wednesday's Pre-Market Session

Financial news for RIGL dated on 2018-04-18: Rigel Pharma Shares Spiking Premarket on Heavy Volume Following FDA Approval of Tavalisse Announced Tuesday

Financial news for RIGL dated on 2018-04-17: Rigel Pharmaceuticals Shares Up 5.6% After Hours Following Announcement Of FDA Approval For TAVALISSE

Financial news for RIGL dated on 2018-04-17: Rigel Pharma Shares Resume Trade, Spike ~8% Higher

Financial news for RIGL dated on 2018-04-17: Rigel Pharma Press Release Confirms FDA Approval of TAVALISSE, Shares Remain Halted

Financial news for RIGL dated on 2018-04-17: UPDATE: FDA Access Data .gov Site Shows FDA Approved 100, 150mg Tavalisse By Riconpharma LLC

Financial news for RIGL dated on 2018-04-17: Rigel Pharma Shares Halted With Code News Pending

Financial news for RIGL dated on 2018-04-17: Traders Attributing Move Higher In Rigel Pharma, Circuit Breaker To Report Of FDA Approval For TAVALISSE

Financial news for RIGL dated on 2018-04-17: Rigel Pharmaceuticals Halted On Circuit Breaker, Up 10.19% At \$4.11/Share

Financial news for RIGL dated on 2018-04-17: REMINDER: FDA PDUFA Dates Today Include: Ultragenyx BLA for Burosumab and Rigel Pharma for Fostamatinib

Financial news for RIGL dated on 2018-04-16: The Week Ahead: Netflix Earnings, Big Bank Results, FDA Actions Abound

Financial news for RIGL dated on 2018-04-13: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for RIGL dated on 2018-04-13: 41 Biggest Movers From Yesterday

Financial news for RIGL dated on 2018-04-12: UPDATE: Rigel Says FDA Continues To Review NDA, PDUFA Action Date Of Apr. 17, '18

Financial news for RIGL dated on 2018-04-12: UPDATE: Rigel Says Website Has Been Corrected

Financial news for RIGL dated on 2018-04-12: UPDATE: Rigel Cites Error By External Host Of IR Website, Inaccurate Info Was Displayed Related To FDA Review Of NDA For Fostamatib

Financial news for RIGL dated on 2018-04-12: '...\$RIGL...spox blames Nasdaq. "NASDAQ inadvertently issued a release today. You can contact them for more details on that. Rigel continues to anticipate FDA action on TAVALISSE on or around April 17."'

Financial news for RIGL dated on 2018-04-12: Shares of Rigel Pharmaceuticals Fell Sharply Following Co. Removing FDA Approval Language With Regard To TAVALISSE From Co. Site

Financial news for RIGL dated on 2018-04-12: Rigel Pharmaceuticals Shares Up 14.3%, Traders Circulating Co. Website Post That TAVALISSE Is The Co.'s First FDA Approved Product

Financial news for RIGL dated on 2018-04-12: Rigel Pharma Option Alert: Apr 20 \$2.5 Puts Sweep (24) at the Bid: 2344 @ \$0.35 vs 23342 OI; Earnings 5/1 After Close [est] Ref=\$3.71

Financial news for RIGL dated on 2018-04-04: 35 Biggest Movers From Yesterday

Financial news for RIGL dated on 2018-04-03: Mid-Afternoon Market Update: Quest Resource Falls Following Q4 Results; Bio-Path Shares Surge

Financial news for RIGL dated on 2018-04-03: 26 Stocks Moving In Tuesday's Mid-Day Session

Financial news for RIGL dated on 2018-04-03: Rigel Pharma Price Target Lowered From \$7 To \$6 By Cantor Fitzgerald, Overweight Rating Reiterated

Financial news for RIGL dated on 2018-04-03: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for RIGL dated on 2018-04-03: 17 Stocks Moving In Tuesday's Pre-Market Session

Financial news for RIGL dated on 2018-04-03: Rigel Did Not Achieve Primary Endpoint For Phase 2 Study Of Fostamatinib In IgA Nephropathy

Financial news for RIGL dated on 2018-03-30: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials And Conferences

Financial news for RIGL dated on 2018-03-28: Rigel Pharma Option Alert: Apr 20 \$5 Calls at the Ask: 5000 @ \$0.7 vs 5611 OI; Earnings 5/1 After Close [est] Ref=\$3.625

Financial news for RIGL dated on 2018-03-08: 41 Biggest Movers From Yesterday

Financial news for RIGL dated on 2018-03-06: Rigel Pharma Reports Q4 EPS \$(0.18) vs \$(0.13) Est., Sales \$0

Financial news for RIGL dated on 2018-03-06: Rigel Pharmaceuticals Q4 Earnings Outlook

Financial news for RIGL dated on 2018-03-02: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for RIGL dated on 2018-02-01: Rigel Pharma Shares Make Parabolic Move, Now Lower; Traders Circulate FDA.gov Access Data Alert Showing Orphan Drug Designation For Fostamatinib

Financial news for RIGL dated on 2017-12-15: Benzinga's Top Upgrades, Downgrades For December 15, 2017

Financial news for RIGL dated on 2017-12-15: Cantor Fitzgerald Initiates Coverage On Rigel Pharmaceuticals with Overweight Rating, Announces \$6.00 Price Target

Financial news for RIGL dated on 2017-12-15: Rigel Pharma Reports CFO Ryan Maynard To Resign; VP, Finance Nelson Cabatuan Will Serve As Co.'s Interim Principal Accounting Officer

Financial news for RIGL dated on 2017-11-07: Rigel Pharmaceuticals Reports Q3 EPS \$(0.14) vs \$(0.15) Est., Sales \$900K vs \$3.76M In Same Qtr. Last Year

Financial news for RIGL dated on 2017-11-06: Benzinga's Top Upgrades, Downgrades For

November 6, 2017

Financial news for RIGL dated on 2017-11-06: H.C. Wainwright Assumes Rigel Pharmaceuticals at Buy, Announces price target \$7.00

Financial news for RIGL dated on 2017-10-31: Rigel Pharma To Report Q3 Earnings On Tues., Nov. 7 After Market Close

Financial news for RIGL dated on 2017-10-05: Rigel Prices 18.1M Share Common Stock Offering @\$3.35/Share

Financial news for RIGL dated on 2017-10-04: Rigel Pharma Shares Recently Turn Positive, Now Up 9% For Session; Stock Up 53% Over Last 5 Trading Sessions

Financial news for RIGL dated on 2017-10-04: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for RIGL dated on 2017-10-04: A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Economic Reports

Financial news for RIGL dated on 2017-10-04: 6 Stocks To Watch For October 4, 2017

Financial news for RIGL dated on 2017-10-03: Rigel Pharma Reports Offering Of \$40M in Common Shares

Financial news for RIGL dated on 2017-10-03: Mid-Day Market Update: Dow Rises 70 Points; RedHill Biopharma Shares Slide

Financial news for RIGL dated on 2017-10-03: Rigel Pharma Shares Up 14% In Tuesday's Premarket, Continuing Run From Mon.; Shares Rallied 32+% On Mon. Following News The FDA Indicated It Will Not Hold An AdCom Meeting For Fostamatinib

Financial news for RIGL dated on 2017-10-03: Rigel Pharmaceuticals Says They Completed Enrollment Of Stage 1 Of Its Phase 2 Study Of fostamatinib

Financial news for RIGL dated on 2017-10-02: Mid-Afternoon Market Update: Dow Gains 130 Points; CyberOptics Shares Plunge

Financial news for RIGL dated on 2017-10-02: Rigel Pharma Shares Up 29.7% Following News FDA Has Indicated It Will Not Hold An Oncology Drugs AdCom Meeting For Fostamatinib

Financial news for RIGL dated on 2017-10-02: 20 Biggest Mid-Day Gainers For Monday

Financial news for RIGL dated on 2017-10-02: Mid-Day Market Update: Crude Oil Down Over 2%; Endocyte Shares Spike Higher

Financial news for RIGL dated on 2017-10-02: Mid-Morning Market Update: Markets Open Higher; Cal-Maine Foods Posts Wider-Than-Expected Loss

Financial news for RIGL dated on 2017-10-02: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for RIGL dated on 2017-10-02: UPDATE: Rigel Says FDA Indicated It Expects Meeting The PDUFA Action Date Of Apr. 17, 2018

Financial news for RIGL dated on 2017-10-02: Rigel Pharma Offers Update On FDA Review Of Fostamatinib For ITP: FDA Has Indicated It Will Not Hold Oncology Drugs AdCom Meeting To Discuss NDA

Financial news for RIGL dated on 2017-09-28: Seeing Notable Block Trade In Rigel Pharmaceuticals, 1.1M Shares At \$2.30/Share

Financial news for RIGL dated on 2017-08-31: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for RIGL dated on 2017-08-14: Rigel Pharma Spikes to High of \$2.43 on Volume

Financial news for RIGL dated on 2017-08-01: Rigel Reports Q2 EPS \$(0.16) vs \$(0.15) Est.

Financial news for RIGL dated on 2017-06-19: 15 Biggest Mid-Day Gainers For Monday

Financial news for RIGL dated on 2017-06-19: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for RIGL dated on 2017-06-19: Rigel Pharma's New Drug Application for TAVALISSE is Accepted by the FDA

Financial news for RIGL dated on 2017-05-02: Rigel Reports Q1 EPS \$(0.13) vs \$(0.12) Est., Sales \$3.584M vs \$3.33M Est.

Financial news for RIGL dated on 2017-04-17: Rigel Submits NDA to FDA For Fostamatinib

Financial news for RIGL dated on 2017-03-09: Mid-Morning Market Update: Markets Edge Higher; Staples Earnings Miss Views

Financial news for RIGL dated on 2017-03-08: Mid-Afternoon Market Update: Dow Falls 50 Points; H & R Block Shares Spike Higher

Financial news for RIGL dated on 2017-03-08: Mid-Day Market Update: Crude Oil Down Over 3%; Express Shares Drop On Weak Forecast

Financial news for RIGL dated on 2017-03-07: Rigel Pharma Reports Q4 EPS \$(0.16) vs \$(0.17) Est., Contract Sales from Collaborations \$3M vs \$4.25M Est.

Financial news for RIGL dated on 2017-02-10: Great Point Partners Llc Reports 7.47% Passive Stake in Rigel Pharmaceuticals as of January 31, 2017 in 13G

Financial news for RIGL dated on 2017-01-31: Rigel Pharma Prices Offering of 20M Shares at \$2/Share

Financial news for RIGL dated on 2017-01-30: Rigel Reports Proposed Public Offering Of Common Stock, Size Not Disclosed

Financial news for RIGL dated on 2017-01-30: Rigel Announces Offering Of Common Stock, No Size Disclosed

Financial news for RIGL dated on 2017-01-30: Rigel Pharma Reports Updates from Clinical Program of Fostamatinib in Patients with Chronic ITP

Financial news for RIGL dated on 2016-12-27: Why The Last Week Of 2016 Could Be Big For Biotech Catalysts

Financial news for RIGL dated on 2016-12-05: 10 Stocks With Lowest Close In Three Weeks

Financial news for RIGL dated on 2016-11-01: Rigel Announces Q3 Loss/Share \$0.24 vs Est Loss/Share \$0.23, Revenue \$3.76M vs \$3.97M Est

Financial news for RIGL dated on 2016-11-01: Rigel Says It Expects To Submit NDA On FIT Fostamatinib Treatment In Q1 2017

Financial news for RIGL dated on 2016-10-20: Mid-Afternoon Market Update: Crude Oil Down Over 2.5%; American Express Shares Gain On Earnings Beat

Financial news for RIGL dated on 2016-10-20: 18 Biggest Mid-Day Losers For Thursday

Financial news for RIGL dated on 2016-10-20: Mid-Day Market Update: Insteel Industries Drops Following Q4 Results; DragonWave Shares Spike Higher

Financial news for RIGL dated on 2016-10-20: Rigel Pharma Shares Suffering After Phase 3 Study Failure

Financial news for RIGL dated on 2016-10-20: Mid-Morning Market Update: Markets Mostly Higher; Verizon Posts Mixed Q3 Results

Financial news for RIGL dated on 2016-10-20: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for RIGL dated on 2016-10-20: Rigel Pharma Shares to Resume Trade at 7:30 a.m. EDT

Financial news for RIGL dated on 2016-10-20: Rigel Reports Results from Second FIT Phase 3 Study, Long-Term Open-Label Extension Study for Fostamatinib in ITP: Difference Between Treatment, Placebo Did Not Reach Statistical Significance, Did Not Meet Primary Endpoint

Financial news for RIGL dated on 2016-10-20: Rigel Pharma Halted, News Pending

Financial news for RIGL dated on 2016-10-18: 18 Stocks Which Plummetered Three Days On Increasing Volume

Financial news for RIGL dated on 2016-10-04: Stocks Hitting 52-Week Highs

Financial news for RIGL dated on 2016-09-29: Watch These 5 Huge Call Purchases In



## Thursday Trade

Financial news for RIGL dated on 2016-09-28: Option Alert: RIGL Dec16 2.5 Calls: 3250 @ ASK \$1.55: 3260 traded vs 415 OI: Earnings 11/1 \$3.59 Ref

Financial news for RIGL dated on 2016-09-28: Option Alert: RIGL Dec16 7.5 Calls Sweep: 500 @ ASK \$0.25: 500 traded vs 20 OI: Earnings 11/1 \$3.45 Ref

Financial news for RIGL dated on 2016-09-15: UPDATE: Rigel Names Eldon Mayer Chief Commercial Officer

Financial news for RIGL dated on 2016-09-15: Rigel Restructures to Focus on Fostamatinib Commercialization, To Reduce Workforce By 38% By Eliminating 46 Positions in Research Area; Will Incur \$5.7M Cash-Related Expense

Financial news for RIGL dated on 2016-09-01: 7 Biggest Price Target Changes For Thursday

Financial news for RIGL dated on 2016-09-01: BMO Thinks Rigel's Fostamatinib Market Opportunity Will Be Further Validated

Financial news for RIGL dated on 2016-08-31: 12 Biggest Mid-Day Losers For Wednesday

Financial news for RIGL dated on 2016-08-31: 12 Stocks Moving In Wednesday's Pre-Market Session

Financial news for RIGL dated on 2016-08-30: Mid-Afternoon Market Update: Crude Oil Down 1.3%; Ritchie Bros. Shares Spike Higher

Financial news for RIGL dated on 2016-08-30: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for RIGL dated on 2016-08-30: Mid-Day Market Update: Abercrombie & Fitch Drops On Wider Loss; Rigel Pharmaceuticals Shares Surge

Financial news for RIGL dated on 2016-08-30: Jefferies Positive On Rigel Pharma, Sees Potential Upside, Maintains Buy & Raises PT From \$7.00 to \$8.50 Citing Fosta Success

Financial news for RIGL dated on 2016-08-30: Mid-Morning Market Update: Markets Mostly Flat; G-III Apparel Misses Q2 Expectations

Financial news for RIGL dated on 2016-08-30: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for RIGL dated on 2016-08-30: Rigel's Oral Spleen Tyrosine Kinase Inhibitor Meets Primary Endpoint In Final Stage Trial In Chronic ITP

Financial news for RIGL dated on 2016-08-30: BZ NOTE: Rigel Shares Volatile Pre-Market, Traders Skeptical Of Safety Data; 18% Stable Platelet Response vs. Placebo

Financial news for RIGL dated on 2016-08-30: Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP

Financial news for RIGL dated on 2016-08-01: BMO Analysts Initiate Coverage On Rigel Pharma, Seeing 65% Upside

Financial news for RIGL dated on 2016-08-01: Benzinga's Top Initiations

Financial news for RIGL dated on 2016-08-01: BMO Capital Initiates Coverage on Rigel Pharmaceuticals at Outperform

Financial news for RIGL dated on 2016-07-13: Soaring +11% In Pre-Market, Rigel Receives Buy Initiation Amid Fostamatinib Phase 3 Optimism

Financial news for RIGL dated on 2016-07-13: H.C. Wainwright Initiates Coverage on Rigel Pharmaceuticals at Buy

Financial news for RIGL dated on 2016-06-13: Piper Jaffray Initiates Coverage on Rigel Pharmaceuticals at Overweight

Financial news for RIGL dated on 2016-05-03: Rigel Reports Inline Q1 EPS \$(0.19), Sales \$5M Vs Est \$4M

Financial news for RIGL dated on 2016-04-22: Rigel Pharma Gets Bulls From JPMorgan Before New Phase 3 Data: What To Know

Financial news for RIGL dated on 2016-04-22: JP Morgan Upgrades Rigel Pharmaceuticals to Overweight

Financial news for RIGL dated on 2016-04-01: Rigel Announces Enrollment Completion of

### Phase 3 Program

Financial news for RIGL dated on 2016-03-16: Option Alert: RIGL Sep16 2.5 Calls Sweep: 500 @ ASK \$0.60: 500 traded vs 1815 OI: Earnings 5/5 \$2.28 Ref

Financial news for RIGL dated on 2016-03-08: Rigel Reports Q4 EPS \$(0.14) vs. Est. \$(0.14), Rev. \$8.5M vs. Est. \$8.9M

Financial news for RIGL dated on 2016-03-08: Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer

Financial news for RIGL dated on 2016-02-29: Option Alert: RIGL Sep16 2.5 Calls Sweep: 500 @ ASK \$0.54: 500 traded vs 241 OI: Earnings tmrrw \$2.31 Ref

Financial news for RIGL dated on 2016-02-25: Rigel Begins Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia

Financial news for RIGL dated on 2016-01-28: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP

Financial news for RIGL dated on 2015-11-03: Rigel Reports Q3 EPS \$(0.08) vs. Est. \$(0.17), Rev. \$13M vs. Est. \$5M; Est. May Not Compare

Financial news for RIGL dated on 2015-09-09: Rigel, Aclaris Therapeutics Sign JAK Inhibitors License Agreement

Financial news for RIGL dated on 2015-09-08: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP

Financial news for RIGL dated on 2015-08-04: Rigel Reports Q2 EPS \$1.57 vs. Est. \$(0.22) Does Not Compare, Rev. \$1.541M vs. Est. \$2.67M May Not Compare

Financial news for RIGL dated on 2015-07-01: Rigel Shares Spike Higher; May be Attributed to Article 'Experimental drug combined with standard chemo may shrink ovarian cancers'

Financial news for RIGL dated on 2015-05-07: S-3 from Rigel Pharma Shows Registration for \$150M Mixed Securities Shelf Offering

Financial news for RIGL dated on 2015-03-04: Shares of Rigel Pull Back on Report They are Not Partners with Bristol Myers on Opdivo for Lung Cancer

Financial news for RIGL dated on 2015-03-03: Rigel Pharmaceuticals Reports Q4 EPS -\$0.25 Vs Est -\$0.26

Financial news for RIGL dated on 2015-03-03: Earnings Scheduled For March 3, 2015

Financial news for RIGL dated on 2015-02-23: Biotech Stocks Moving Higher

Financial news for RIGL dated on 2015-02-23: Morning Market Gainers

Financial news for RIGL dated on 2015-02-23: Monday's #PreMarket Movers: Spectrum Pharmaceuticals, Cyberark Software Trending Down

Financial news for RIGL dated on 2015-02-23: Benzinga's Top #PreMarket Gainers

Financial news for RIGL dated on 2015-02-23: Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications

Financial news for RIGL dated on 2015-01-15: Rigel Sees Current Cash Sufficient To Fund Operations through Q4 2016

Financial news for RIGL dated on 2015-01-15: From Webcast: Rigel Sees Results From Phase 3 Trials In 1H 2016; Targets Approval For Fostamatinib End of 2017

Financial news for RIGL dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

Financial news for RIGL dated on 2015-01-08: UPDATE: Rigel Sees Ending 2015 With Cash Sufficient For Operations Through Fourth Quarter 2016

Financial news for RIGL dated on 2015-01-08: UPDATE: Rigel Earns \$5.75M Payment From AstraZeneca; Sees Ending 2015 With Cash Equivalents of \$68M

Financial news for RIGL dated on 2015-01-08: Rigel Pharmaceuticals To Present at J.P. Morgan Healthcare Conference; Provides Company Updates

Financial news for RIGL dated on 2014-11-24: Rigel Pharmaceuticals CEO James Gower To

Retire; Raul Rodriguez As Successor

Financial news for RIGL dated on 2014-11-04: Rigel Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.24) vs \$(0.27) Est

Financial news for RIGL dated on 2014-08-29: What You Need to Know About the Roche-InterMune Deal

Financial news for RIGL dated on 2014-08-25: InterMune's Roche Deal Sends Peer Group Up

Financial news for RIGL dated on 2014-08-13: Morning Market Losers

Financial news for RIGL dated on 2014-08-13: Rigel Pharma Reports R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study

Financial news for RIGL dated on 2014-08-05: Rigel Pharmaceuticals Says There Was No Contract Revenue from Collaborations In Q2 2014; Says Anticipates Reporting Top-Line Results from Phase 2 R348 Study In Patients With Dry Eye Soon

Financial news for RIGL dated on 2014-08-05: Rigel Pharmaceuticals Reports Q2 EPS of \$(0.29) vs \$(0.25) Est

Financial news for RIGL dated on 2014-07-16: Rigel Initiates Phase 3 Studies Of Fostamatinib In ITP

Financial news for RIGL dated on 2014-06-02: Corporate Events for the Week of Jun. 2nd, 2014

Financial news for RIGL dated on 2014-05-07: Rigel Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.25), Inline

Financial news for RIGL dated on 2014-03-06: Benzinga's Top #PreMarket Gainers

Financial news for RIGL dated on 2014-03-04: Rigel Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.19) vs \$(0.25) Est

Financial news for RIGL dated on 2014-03-04: Earnings Scheduled For March 4, 2014

Financial news for RIGL dated on 2013-12-30: Stocks to Watch for December 30, 2013

Financial news for RIGL dated on 2013-11-05: Rigel Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.27) vs \$(0.29) Est

Financial news for RIGL dated on 2013-10-24: Shares of Rigel Pharma to Resume Trade at 8AM EDT

Financial news for RIGL dated on 2013-10-24: PREVIEW: Rigel Pharmaceuticals to Resume Trading at 8:00 AM ET

Financial news for RIGL dated on 2013-10-24: Rigel Pharma Says R333 Did Not Meet Primary Endpoint

Financial news for RIGL dated on 2013-10-24: Shares of Rigel Pharma Halted News Pending

Financial news for RIGL dated on 2013-09-05: Benzinga's Top Pre-Market Losers

Financial news for RIGL dated on 2013-09-05: Rigel Pharma Says Will Not Continue Further Development of Fostamatinib for RA, Lymphoma, Cites Insufficient Efficacy Findings, Cutting ~30 Jobs

Financial news for RIGL dated on 2013-08-26: Leerink Swann Reiterates Outperform On Rigel Pharma As Shares Plunge 12+% On Missed R343 Trial Endpoints

Financial news for RIGL dated on 2013-08-26: Morning Market Losers

Financial news for RIGL dated on 2013-08-26: Benzinga's Top Pre-Market Losers

Financial news for RIGL dated on 2013-08-26: Shares of Rigel Pharma Resume Trade Down 33%

Financial news for RIGL dated on 2013-08-26: Shares of Rigel Pharma to Resume Trade at 8AM EDT

Financial news for RIGL dated on 2013-08-26: UPDATE: Rigel Pharma Announces R343 Did Not Meet Primary, Secondary Endpoints in Asthma Trial

Financial news for RIGL dated on 2013-08-26: Shares of Rigel Pharm Halted to Announce

## R343 Did Not Meet Primary Endpoint

Financial news for RIGL dated on 2013-08-02: Weekly Preview: Earnings Season Nears The End, China in Focus

Financial news for RIGL dated on 2013-06-05: UPDATE: Jefferies Lowers PT on Rigel Pharmaceuticals Following Return of Fostamatinib Rights

Financial news for RIGL dated on 2013-06-05: Jefferies Maintains Buy on Rigel Pharmaceuticals, Inc., Lowers PT to \$6.00

Financial news for RIGL dated on 2013-06-04: Market Wrap for Tuesday, June 4: Stocks Retreat as Uncertainty Rises

Financial news for RIGL dated on 2013-06-04: Afternoon Market Losers

Financial news for RIGL dated on 2013-06-04: UPDATE: Oppenheimer Downgrades Rigel Pharmaceuticals on Disappointing Ph.III OKSIRA-2/3 Studies

Financial news for RIGL dated on 2013-06-04: UPDATE: J.P. Morgan Downgrades Rigel Pharmaceuticals to Neutral Following AZN Decision

Financial news for RIGL dated on 2013-06-04: Traders Passing Around Fool Article 'AstraZeneca Writes Off \$140 Million Following Product Trial' Related to Results from Fostamatinib

Financial news for RIGL dated on 2013-06-04: Stocks Hitting 52-Week Lows

Financial news for RIGL dated on 2013-06-04: Oppenheimer Downgrades Rigel Pharmaceuticals, Inc. to Perform, Removes \$10.00 PT

Financial news for RIGL dated on 2013-06-04: Morning Market Losers

Financial news for RIGL dated on 2013-06-04: Canaccord Genuity Maintains Hold on Rigel Pharmaceuticals, Inc., Lowers PT to \$4.00

Financial news for RIGL dated on 2013-06-04: JP Morgan Downgrades Rigel Pharmaceuticals, Inc. to Neutral

Financial news for RIGL dated on 2013-06-04: Oppenheimer Downgrades Rigel Pharmaceuticals, Inc. to Perform

Financial news for RIGL dated on 2013-06-04: UPDATE: Piper Jaffray Downgrades Rigel Pharmaceuticals on the Return of Fostamatinib

Financial news for RIGL dated on 2013-06-04: Benzinga's Top Pre-Market Losers

Financial news for RIGL dated on 2013-06-04: Benzinga's Top Downgrades

Financial news for RIGL dated on 2013-06-04: Piper Jaffray Downgrades Rigel Pharmaceuticals, Inc. to Neutral, Lowers PT to \$6.00

Financial news for RIGL dated on 2013-06-04: Rigel, AstraZeneca Announce Topline Results from OSKIRA-2 and OSKIRA-3 Phase 3 Clinical Trials Investigating Fostamatinib

Financial news for RIGL dated on 2013-05-07: Rigel Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.29) vs \$(0.30) Est

Financial news for RIGL dated on 2013-04-22: 9 Technical Setups for the Week Ahead

Financial news for RIGL dated on 2013-04-19: Stocks to Watch for April 19, 2013

Financial news for RIGL dated on 2013-04-18: Stocks to Watch for April 18, 2013

Financial news for RIGL dated on 2013-04-11: Stocks to Watch for April 11, 2013

Financial news for RIGL dated on 2013-04-05: Morning Market Losers

Financial news for RIGL dated on 2013-04-05: UPDATE: BMO Capital Markets Downgrades Rigel Pharmaceuticals to Market Perform on Mixed OSKIRA-1 Results

Financial news for RIGL dated on 2013-04-05: Mid-Morning Market Update: Markets Tumble, F5 Networks Cuts View

Financial news for RIGL dated on 2013-04-05: BMO Capital Downgrades Rigel Pharmaceuticals, Inc. to Market Perform, Lowers PT to \$8.00

Financial news for RIGL dated on 2013-04-05: AstraZeneca Announces Results from OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis

Financial news for RIGL dated on 2013-03-06: Citigroup Maintains Neutral on Rigel Pharmaceuticals, Inc., Raises PT to \$7.00

Financial news for RIGL dated on 2013-03-05: UPDATE: JP Morgan Maintains Rigel Pharmaceuticals at Overweight Post 4Q Results

Financial news for RIGL dated on 2013-03-05: UPDATE: Piper Jaffray Raises PT to \$9 on Rigel Pharmaceuticals Ahead of Fostamatinib Readout

Financial news for RIGL dated on 2013-03-05: Piper Jaffray Maintains Overweight on Rigel Pharmaceuticals, Inc., Raises PT to \$9.00

Financial news for RIGL dated on 2013-03-05: Rigel Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.30) vs \$(0.32) Est

Financial news for RIGL dated on 2013-03-05: Earnings Scheduled For March 5, 2013

Financial news for RIGL dated on 2013-02-19: Option Alert: Rigel Pharmaceuticals June 10/15 Call Spread; 1,441 Contracts Traded at \$0.85, Currently \$6.74

Financial news for RIGL dated on 2012-12-14: UPDATE: Stifel Nicolaus Cuts PT to Rigel Pharmaceuticals on Model Changes Post Data

Financial news for RIGL dated on 2012-12-14: Stifel Nicolaus Maintains Buy on Rigel Pharmaceuticals, Inc., Lowers PT to \$11.00

Financial news for RIGL dated on 2012-12-13: Mid-Afternoon Market Update: SolarCity Hangs on to Gains, Rigel Pharma Continues to Hurt

Financial news for RIGL dated on 2012-12-13: JP Morgan Maintains Overweight on Rigel Pharmaceuticals, Inc., Lowers PT to \$10.00

Financial news for RIGL dated on 2012-12-13: UPDATE: Jefferies Cuts PT to \$15 on Rigel Pharmaceuticals on Disappointing Fostamatinib Results

Financial news for RIGL dated on 2012-12-13: Mid-Day Market Update: Markets Go Red, SolarCity IPO a Success

Financial news for RIGL dated on 2012-12-13: UPDATE: Piper Jaffray Cuts PT to \$8 on Rigel Pharmaceuticals Following Disappointing Phase II Results

Financial news for RIGL dated on 2012-12-13: Rigel Pharma Shares Sink as Fostamatinib Fails to Hit Secondary Endpoint

Financial news for RIGL dated on 2012-12-13: Citigroup Downgrades Rigel Pharmaceuticals, Inc. to Neutral, Lowers PT to \$6.00

Financial news for RIGL dated on 2012-12-13: Mid-Morning Market Update: Markets Cautiously Rising, Best Buy Boosts

Financial news for RIGL dated on 2012-12-13: Jefferies Maintains Buy on Rigel Pharmaceuticals, Inc., Lowers PT to \$15.00

Financial news for RIGL dated on 2012-12-13: Piper Jaffray Maintains Overweight on Rigel Pharmaceuticals, Inc., Lowers PT to \$8.00

Financial news for RIGL dated on 2012-12-13: Stocks Hitting 52-Week Lows

Financial news for RIGL dated on 2012-12-13: Morning Market Losers

Financial news for RIGL dated on 2012-12-13: Benzinga's Top Pre-Market Losers

Financial news for RIGL dated on 2012-11-29: UBS Initiates Coverage on Rigel Pharmaceuticals, Inc. at Neutral, Announces \$9.00 PT

Financial news for RIGL dated on 2012-11-07: UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Rigel Pharmaceuticals

Financial news for RIGL dated on 2012-11-07: Jefferies & Company Maintains Rigel Pharmaceuticals at Buy, Raises PT from \$14 to \$21

Financial news for RIGL dated on 2012-11-06: From Earlier: Rigel Pharmaceuticals Reports Q3 EPS \$-0.36 vs \$-0.32 Est

Financial news for RIGL dated on 2012-10-15: UPDATE: Piper Jaffray Reiterates Overweight Rating, Lowers PT on Rigel Pharmaceuticals

Financial news for RIGL dated on 2012-10-15: Piper Jaffray Maintains Rigel

Pharmaceuticals at Overweight, Lowers PT from \$16 to \$14

Financial news for RIGL dated on 2012-10-03: Benzinga Mid-Day Market Update

Financial news for RIGL dated on 2012-10-03: Rigel Announces Pricing Of 13.685M Share Public Offering at \$9.50 per Share

Financial news for RIGL dated on 2012-10-03: Benzinga's Top Pre-Market Losers

Financial news for RIGL dated on 2012-10-02: Rigel Announces Proposed Public Offering Of Common Stock

Financial news for RIGL dated on 2012-08-07: JP Morgan Maintains Rigel Pharmaceuticals at Overweight, Raises PT from \$14 to \$15

Financial news for RIGL dated on 2012-08-07: Rigel Pharmaceuticals Reports Q2 EPS \$-0.35 vs \$-0.35 Est

Financial news for RIGL dated on 2012-07-10: Dendreon, Pharmacyclics and Other Biotech Takeover Targets

Financial news for RIGL dated on 2012-06-21: Option Alert: Rigel Pharmaceuticals December 10 Call; Block Trade: 2,159 Contracts; Currently \$8.81

Financial news for RIGL dated on 2012-06-19: AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma

Financial news for RIGL dated on 2012-05-10: Option Alert: Rigel Pharmaceuticals May 7.5 Put; Block Trade: 2,500 Contracts

Financial news for RIGL dated on 2012-05-01: Rigel Pharmaceuticals Reports Q1 EPS \$-0.32 vs \$-0.31 Est

Financial news for RIGL dated on 2012-04-24: Option Alert: Rigel Pharmaceuticals December 10 Call; Block Trade: 2,500 Contracts

Financial news for RIGL dated on 2012-03-26: Canaccord Initiates Coverage on Rigel Pharmaceuticals at Hold, Announces PT of \$8

Financial news for RIGL dated on 2012-03-06: Piper Jaffray Reiterates Overweight on Rigel Pharmaceuticals ahead of Phase III Data

Financial news for RIGL dated on 2012-02-22: Benzinga's Top Upgrades

Financial news for RIGL dated on 2012-02-22: Financial Breakfast: Morning News Summary for February 22, 2012

Financial news for RIGL dated on 2012-02-22: Citigroup Upgrades Rigel Pharmaceuticals from Neutral to Buy, Maintains PT at \$13

Financial news for RIGL dated on 2012-01-05: Rigel Announces Initiation of Clinical Trials in Two Immunology Programs

Financial news for RIGL dated on 2012-01-05: Rigel Announces Initiation of Clinical Trials in Two Immunology Programs

Financial news for RIGL dated on 2011-11-10: Piper Jaffray Maintains OW, PT on Rigel Pharmaceuticals After Consistent Long Term Safety Data

Financial news for RIGL dated on 2011-09-29: J.P. Morgan Initiates Coverage on Rigel Pharmaceuticals

Financial news for RIGL dated on 2011-09-29: JP Morgan Initiates Rigel Pharmaceuticals at Overweight, \$14 PT

Financial news for RIGL dated on 2011-08-02: Rigel Pharmaceuticals Reports Q2 EPS \$(0.37) vs \$(0.38) Est; Revenues \$395K vs \$420.00K Est

Financial news for RIGL dated on 2011-05-26: Calls Purchased on Rigel Pharmaceuticals

Financial news for RIGL dated on 2011-05-26: Rigel Announces Prices Public Offering of 16.3M Shares at \$8.00 per Share

Financial news for RIGL dated on 2011-05-26: Benzinga's Top Pre-Market NASDAQ Losers

Financial news for RIGL dated on 2011-05-25: Rigel Announces Proposed Public Offering of Common Stock

Financial news for RIGL dated on 2011-05-06: Rigel Assumes Development Responsibility

for Inhaled Asthma Therapy (RIGL)

Financial news for RIGL dated on 2011-05-04: Jefferies Believes In A Long-Term Upside for RIGL

Financial news for RIGL dated on 2011-03-03: Citigroup Updates Rigel Pharmaceuticals After Healthcare Conferences (RIGL)

Financial news for RIGL dated on 2011-03-01: Rigel Pharmaceuticals Reports Uneventful 4Q

Financial news for RIGL dated on 2010-12-10: Wells Fargo Initiating Coverage On RIGL With An Outperform Rating And A \$10-12 Valuation Range

Financial news for RIGL dated on 2010-06-02: Benzinga's After Hours Decliners (EOG, RGL, BKE)

Financial news for RIGL dated on 2010-03-26: RIGL Highlights Clinical and Preclinical Pipeline

Financial news for RIGL dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for RIGL dated on 2010-02-22: Benzinga's Top Pre-Market Losers (RIGL, FSLR, GILD, STP, GSK)

Financial news for RIGL dated on 2010-02-16: Movement Expected In The Shares Of These Companies Amid Significant Events (BRK.B, BX, JPM, ORCL, YHOO)

Financial news for RIGL dated on 2010-02-16: Rigel Pharmaceuticals, Inc. (RIGL) Maintains An 1-Overweight Rating

Financial news for RIGL dated on 2010-02-16: Pharmaceutical Giants AstraZeneca (AZN), Rigel (RIGL) Collaborate On Arthritis Drug

Financial news for RIGL dated on 2010-02-16: Company News for February 16, 2010 - Corporate Summary

Financial news for RIGL dated on 2010-02-16: Benzinga's Top Pre-Market Gainers (NIHD, RIGL, APWR, RTIX, ARTG)